Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27,285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
Woo SJ, Veith M, Hamouz J, Ernest J, Zalewski D, Studnicka J, Vajas A, Papp A, Gabor V, Luu J, Matuskova V, Yoon YH, Pregun T, Kim T, Shin D, Bressler NM. Woo SJ, et al. Among authors: kim t. JAMA Ophthalmol. 2021 Jan 1;139(1):68-76. doi: 10.1001/jamaophthalmol.2020.5053. JAMA Ophthalmol. 2021. PMID: 33211076 Free PMC article. Clinical Trial.
Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes.
Bressler NM, Veith M, Hamouz J, Ernest J, Zalewski D, Studnička J, Vajas A, Papp A, Vogt G, Luu J, Matuskova V, Yoon YH, Pregun T, Kim T, Shin D, Oh I, Jeong H, Kim MY, Woo SJ. Bressler NM, et al. Among authors: kim t, kim my. Br J Ophthalmol. 2023 Mar;107(3):384-391. doi: 10.1136/bjophthalmol-2021-319637. Epub 2021 Oct 16. Br J Ophthalmol. 2023. PMID: 34656987 Free PMC article. Clinical Trial.
Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial.
Woo SJ, Bradvica M, Vajas A, Sagong M, Ernest J, Studnicka J, Veith M, Wylegala E, Patel S, Yun C, Orski M, Astakhov S, Tóth-Molnár E, Csutak A, Enyedi L, Kim T, Oh I, Jang H, Sadda SR. Woo SJ, et al. Among authors: kim t. JAMA Ophthalmol. 2023 Jul 1;141(7):668-676. doi: 10.1001/jamaophthalmol.2023.2260. JAMA Ophthalmol. 2023. PMID: 37289448 Free PMC article. Clinical Trial.
Secondary hemorrhage in traumatic hyphema.
Volpe NJ, Larrison WI, Hersh PS, Kim T, Shingleton BJ. Volpe NJ, et al. Among authors: kim t. Am J Ophthalmol. 1991 Nov 15;112(5):507-13. doi: 10.1016/s0002-9394(14)76850-3. Am J Ophthalmol. 1991. PMID: 1951586
Computational Hyperspectral Microflow Cytometry.
Yun HG, Cadierno YA, Kim TW, Muñoz-Barrutia A, Garica-Gonzalez D, Choi S. Yun HG, et al. Among authors: kim tw. Small. 2024 May 21:e2400019. doi: 10.1002/smll.202400019. Online ahead of print. Small. 2024. PMID: 38770741
Mycoproteins and their health-promoting properties: Fusarium species and beyond.
Lee D, Pan JH, Kim D, Heo W, Shin EC, Kim YJ, Shim YY, Reaney MJT, Ko SG, Hong SB, Cho HT, Kim TG, Lee K, Kim JK. Lee D, et al. Among authors: kim tg. Compr Rev Food Sci Food Saf. 2024 May;23(3):e13365. doi: 10.1111/1541-4337.13365. Compr Rev Food Sci Food Saf. 2024. PMID: 38767863 Review.
Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
Armstrong AJ, Geva R, Chung HC, Lemech C, Miller WH Jr, Hansen AR, Lee JS, Tsai F, Solomon BJ, Kim TM, Rolfo C, Giranda V, Ren Y, Liu F, Kandala B, Freshwater T, Wang JS. Armstrong AJ, et al. Among authors: kim tm. Invest New Drugs. 2024 May 20. doi: 10.1007/s10637-024-01444-0. Online ahead of print. Invest New Drugs. 2024. PMID: 38767685 No abstract available.
27,285 results
You have reached the last available page of results. Please see the User Guide for more information.